Jacob HansenCEO at Vesper BioSpeaker
Profile
Jacob Falck Hansen is CEO of Vesper Bio, a clinical stage biotech company developing novel treatments for neuropsychiatric diseases. He is also a Partner at Lundbeckfonden BioCapital, the biotech venture capital unit of the Lundbeck Foundation, and currently serves as board director at Notify Therapeutics and Kvantify, and as a board observer at SNIPR Biome.
Jacob has more than 15 years of leadership experience from the pharmaceutical and biotech industry. Prior to joining Vesper Bio and Lundbeckfonden BioCapital, he was responsible for corporate strategy at Novo Nordisk A/S and acted as a trusted advisor to its executive management and board of directors. Jacob holds a MSc in Biochemistry and a PhD from the University of Copenhagen.
Agenda Sessions
Building a Winning Commercialization Strategy for First-in-Class Therapies
, 10:50amView Session